Study identification

EU PAS number

EUPAS23879

Study ID

28608

Official title and acronym

Use of degarelix among patients with prostate cancer in daily practice

DARWIN EU® study

No

Study countries

United Kingdom

Study description

A population-based cohort study will be carried out using the UK’s general practitioner database, Optimum Patient Care Research Database (OPCRD), which includes prostate cancer patients initiating treatment of degarelix, leuprorelin, goserelin or triptorelin from 2010 till present. In this study, we will describe the characteristics, cardio events and urinary tract infections among patients with prostate cancer using degarelix, leuprorelin, goserelin or triptorelin in UK’s primary care.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

Harvey Walsh
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable